| Study | Anthracycline | Number of Patients | Type of Breast Cancer | Cumulative Dose Administered | Definition of Cardiomyopathy | Incidence of anthracycline-mediated Cardiotoxicity |
| Jensen et al. (2002)[39] | epirubicin | 120 | recurrent metastatic breast cancer | 1000 mg/m2 epirubicin, | Clinical symptoms of CHF or decline in LVEF | 15% of the patients experienced a 25% relative reduction in LVEF 3 weeks after terminating therapy, increasing to 59% after 3 years |
| Swain et al. (2003) [22] | doxorubicin | 630 | breast carcinoma and small cell lung carcinoma | 400-700 mg/m2 | Drop ≥ 20% in LVEF from baseline, drop ≥ 10% in LVEF from baseline and to below the institution's LLN, or clinical symptoms of CHF | 5% at 400 mg/m2, 16% at 500, 26% at a dose of 550 mg/m2, 48% at a dose of 700 mg/m2, |
| Azambuja et al. (2009)[40] | Epirubicin | 777 | Node-Positive Breast Cancer | EC: epirubicin 60 mg/m2 with cyclophosphamide or HEC: epirubicin 100 mg/m2 with cyclophosphamide | Drop of LVEF <50% or clinical symptoms of CHF | EC, n = .64% (5/777); HEC, n = 1.4% (11/777) |
| Ryberg et al. (2008)[41] | Epirubicin | 1097 | metastatic breast cancer | cumulative dose of 1000 mg/m2 | Clinical symptoms of CHF or decline in LVEF > 15% from its initial value | 11.4% developed CHF |